Monopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has reiterated an "overweight" rating for Monopar Therapeutics, with a price target of $74.00, indicating a potential upside of 131.03% from its previous closing price.
• Five analysts have rated Monopar with a "Buy," and one has a "Hold," leading to a consensus rating of "Moderate Buy" and a target price of $66.00.
• The company's stock has shown a significant movement, closing at $32.03 with a 12-month high of $54.30 and a 5.3% increase recently.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "overweight" rating reiterated by Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. They currently have a $74.00 price target on the stock. Cantor Fitzgerald's price target suggests a potential upside of 116.69% from the company's current price.

Several other research analysts have also recently issued reports on the company. HC Wainwright assumed coverage on Monopar Therapeutics in a research report on Tuesday, August 26th. They issued a "buy" rating and a $70.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Finally, Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.00.

Monopar Therapeutics Stock Down 5.3%

NASDAQ:MNPR traded down $1.91 on Wednesday, hitting $34.15. The stock had a trading volume of 15,130 shares, compared to its average volume of 33,801. The stock has a market cap of $210.71 million, a price-to-earnings ratio of -10.26 and a beta of 1.20. The business's 50-day simple moving average is $37.89 and its two-hundred day simple moving average is $36.77. Monopar Therapeutics has a 52-week low of $2.25 and a 52-week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. As a group, equities research analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Transactions at Monopar Therapeutics

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares of the company's stock, valued at $459,440. This trade represents a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the director directly owned 5,173 shares in the company, valued at $206,920. This trade represents a 76.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock valued at $1,700,160 over the last quarter. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $34,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $44,000. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the 4th quarter valued at approximately $45,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund bought a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $104,000. Institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.